BENSALEM, Pa.–(BUSINESS WIRE)–$NVRO #classaction–Law Offices of Howard G. Smith reminds investors of the October
22, 2018 deadline to file a lead plaintiff motion in the class
action filed on behalf of investors that purchased Nevro Corp. (“Nevro”
or the “Company”) (NYSE: NVRO)
securities between January 8, 2018 and July 12, 2018, inclusive
(the “Class Period”). Nevro investors have until October 22,
2018 to file a lead plaintiff motion.
Investors suffering losses on their Nevro investments are encouraged to
contact the Law Offices of Howard G. Smith to discuss their legal rights
in this class action at 888-638-4847 or by email to email@example.com.
In April 2017, Boston Scientific Corp. filed an action against Nevro,
asserting claims of patent infringement, theft of trade secrets and
tortious interference with contract by recruiting and hiring dozens of
former Boston Scientific Corp. employees.
Then, on July 10, 2018, various analysts reported on a tentative ruling
in Nevro’s ongoing patent litigation against Boston Scientific. The
tentative ruling invalidated at least five of the patents related to
Nevro’s purportedly “proprietary” HF10 therapy and Senza systems. On
this news, Nevro’s share price fell $11.43 per share, or 15.15%, to
close at $64.04 on July 10, 2018, thereby injuring investors.
The complaint filed in this class action alleges that the Company made
materially false and/or misleading statements during the class period
and/or failed to disclose that: (1) Nevro had engaged in a fraudulent
scheme by using protected confidential and proprietary trade secrets and
stolen documents from its competitors to develop and enhance the
Company’s Senza I and Senza II systems; (2) as a result, Nevro’s Senza I
and Senza II systems were not “novel” or “proprietary;” (3) these
practices caused Nevro to be vulnerable to increased litigation expenses
and adverse legal and regulatory action; (4) as a result, Nevro’s U.S.
sales growth was not sustainable; and (5) consequently, defendants’
statements about Nevro’s business, operations, and prospects, were
materially false and/or misleading and/or lacked a reasonable basis.
If you purchased shares of Nevro during the Class Period you may move
the Court no later than October 22, 2018 to ask the Court to
appoint you as lead plaintiff. To be a member of the Class you need not
take any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Howard G. Smith, Esquire, of Law Offices of
Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania
19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by
email to firstname.lastname@example.org,
or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.